Stem Cell Transplant
Bone Marrow/Kidney Transplant for Blood Disorders & Chronic Kidney Disease
This trial is for a combined bone marrow and kidney transplant from a partially matched related donor to treat a blood disorder and kidney disease. The expectation is to have 10 people participate.
CAR T-cell Therapy
TAA-Specific CTL Therapy for Lymphoma
This trial is for patients who have a type of lymph gland disease called Hodgkin or non-Hodgkin lymphoma which has come back, or may come back, or has not gone away after treatment. This is a research study using special immune system cells called tumor associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental therapy.
Stem Cell Transplantation
Stem Cell Transplant for Non-Hodgkin's Lymphoma
This trial is testing a new two-step approach to treating high-risk non-Hodgkin's lymphoma. First, the patient's own blood cells are transplanted. Then, a transplant from another individual is performed. The goal is to improve the chances for long-term control of lymphoma.
Popular Filters
Trials for B-Cell Lymphoma Patients
Checkpoint Inhibitor
Relatlimab + Nivolumab for Lymphoma
This trial is testing two drugs, relatlimab and nivolumab, in children and young adults whose lymphoma has come back or didn't respond to other treatments. These drugs help the immune system recognize and attack cancer cells. The study aims to see if this combination is safe and effective. Nivolumab has demonstrated clinical benefits in multiple tumors, including classical Hodgkin lymphoma.
Acupuncture for Pain Management in Lymphoma
This trial is investigating whether acupuncture can help reduce the need for opioid painkillers in patients experiencing pain from chemotherapy. Acupuncture involves inserting thin needles into specific points on the body to relieve pain. The study aims to see if this method can lessen pain and improve quality of life for these patients.
AH-HA EHR Tool for Heart Health in Cancer Survivors
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Monoclonal Antibodies
Favezelimab + Pembrolizumab for Lymphoma
This trial will study the safety and effectiveness of two drugs, favezelimab and pembrolizumab, when used alone or in combination to treat people with classical Hodgkin lymphoma, diffuse large B-cell lymphoma, and indolent non-Hodgkin lymphoma.
Trials for Large B-Cell Lymphoma Patients
Checkpoint Inhibitor
Relatlimab + Nivolumab for Lymphoma
This trial is testing two drugs, relatlimab and nivolumab, in children and young adults whose lymphoma has come back or didn't respond to other treatments. These drugs help the immune system recognize and attack cancer cells. The study aims to see if this combination is safe and effective. Nivolumab has demonstrated clinical benefits in multiple tumors, including classical Hodgkin lymphoma.
Acupuncture for Pain Management in Lymphoma
This trial is investigating whether acupuncture can help reduce the need for opioid painkillers in patients experiencing pain from chemotherapy. Acupuncture involves inserting thin needles into specific points on the body to relieve pain. The study aims to see if this method can lessen pain and improve quality of life for these patients.
AH-HA EHR Tool for Heart Health in Cancer Survivors
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Trials for CD30 Positive Patients
Monoclonal Antibodies
SGN-35T for Lymphoma
This trial is testing a new drug in adults with certain types of lymphoma that haven't responded to other treatments. The drug works by targeting a protein on cancer cells and delivering a substance that kills them. This drug has shown high selectivity against specific cancer cells and has been approved for treating lymphoma patients.
CAR T-cell Therapy
Immunotherapy for Lymphoma
This trial tests a new treatment where a patient's immune cells are enhanced to better fight cancer. It targets adults whose CD30+ cancer has come back or resisted other treatments. The enhanced cells are designed to specifically attack cancer cells, making the immune system more effective against the disease.
Trials for CD20 Positive Patients
Monoclonal Antibodies
Atezolizumab + BTCT4465A (Mosunetuzumab) for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
This trial is testing a new drug called Mosunetuzumab, both alone and with another drug called atezolizumab, in patients with blood cancers that have not responded to other treatments. These drugs work by helping the immune system find and destroy cancer cells. Atezolizumab is a medication that has been approved for use in various cancers, including breast cancer, and has shown effectiveness when combined with other treatments.
T-Cell Bispecific Antibody
Glofitamab + Obinutuzumab for Non-Hodgkin's Lymphoma
This trial tests glofitamab, a new drug given through an IV that helps immune cells attack cancer cells. It targets patients who need new treatment options because their cancer hasn't responded to existing treatments. The drug works by connecting immune cells to cancer cells, making it easier for the immune system to destroy the cancer. Glofitamab shows promise in treating certain types of blood cancers.
Monoclonal Antibodies
Mosunetuzumab + Polatuzumab Vedotin for Aggressive B-Cell Lymphoma
This trial will compare the effectiveness of mosunetuzumab+polatuzumab vedotin to rituximab+gemcitabine+oxaliplatin in people with relapsed or refractory DLBCL, high-grade B-cell lymphoma, transformed follicular lymphoma, and FL3B.
Phase 3 Trials
Acupuncture for Pain Management in Lymphoma
This trial is investigating whether acupuncture can help reduce the need for opioid painkillers in patients experiencing pain from chemotherapy. Acupuncture involves inserting thin needles into specific points on the body to relieve pain. The study aims to see if this method can lessen pain and improve quality of life for these patients.
Monoclonal Antibodies
Mosunetuzumab + Polatuzumab Vedotin for Aggressive B-Cell Lymphoma
This trial will compare the effectiveness of mosunetuzumab+polatuzumab vedotin to rituximab+gemcitabine+oxaliplatin in people with relapsed or refractory DLBCL, high-grade B-cell lymphoma, transformed follicular lymphoma, and FL3B.
Monoclonal Antibodies
Brentuximab Vedotin + Chemotherapy for Hodgkin's Lymphoma
This trial is studying brentuximab vedotin in combination with chemotherapy to see if it is more effective than chemotherapy alone in treating children with high risk Hodgkin lymphoma.
Trials With No Placebo
Checkpoint Inhibitor
Relatlimab + Nivolumab for Lymphoma
This trial is testing two drugs, relatlimab and nivolumab, in children and young adults whose lymphoma has come back or didn't respond to other treatments. These drugs help the immune system recognize and attack cancer cells. The study aims to see if this combination is safe and effective. Nivolumab has demonstrated clinical benefits in multiple tumors, including classical Hodgkin lymphoma.
Acupuncture for Pain Management in Lymphoma
This trial is investigating whether acupuncture can help reduce the need for opioid painkillers in patients experiencing pain from chemotherapy. Acupuncture involves inserting thin needles into specific points on the body to relieve pain. The study aims to see if this method can lessen pain and improve quality of life for these patients.
AH-HA EHR Tool for Heart Health in Cancer Survivors
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Monoclonal Antibodies
Favezelimab + Pembrolizumab for Lymphoma
This trial will study the safety and effectiveness of two drugs, favezelimab and pembrolizumab, when used alone or in combination to treat people with classical Hodgkin lymphoma, diffuse large B-cell lymphoma, and indolent non-Hodgkin lymphoma.
View More Related Trials
Frequently Asked Questions
Introduction to hodgkin's lymphoma
What are the top hospitals conducting hodgkin's lymphoma research?
When it comes to innovative clinical trials for Hodgkin's lymphoma, several esteemed hospitals are leading the way. In New york City, Memorial Sloan Kettering Cancer Center is at the forefront with six ongoing trials and an impressive history of 41 completed studies dedicated to understanding this complex condition. Since their first recorded trial in 1994, they have been committed to advancing knowledge and treatment options for patients. Meanwhile, Washington University School of Medicine in Saint Louis has emerged as a significant player in Hodgkin's lymphoma research as well. With four active trials and a total of 28 past studies under their belt since initiating their inaugural trial in 1997, they continue to contribute invaluable insights into this challenging disease.
In Omaha, Nebraska, the University of Nebraska Medical Center also stands out with its dedication to finding new solutions for Hodgkin's lymphoma. Like Washington University School of Medicine, they currently have four active trials underway and have conducted a commendable number of 22 previous studies since embarking on their first trial back in 1996.
Moving over to Milwaukee, Wisconsin - The Medical College is making strides with four ongoing clinical investigations focusing on Hodgkin's lymphoma while gaining valuable knowledge through eight previously held studies dating back only two decades from when it all began; that was marked by recording their very pioneering investigation on these cases which took place around2003.And last but certainly not least - MD Anderson Cancer Center located in Houston has also demonstrated its commitment by conducting four current hodgkins' lymphoma clinical tests while adding up sixteen more experiments from starting its investigative journey regarding these conditions merely eighteen years ago
These institutions serve as beacons of hope for individuals battling Hodgkin's lymphoma worldwide. Their relentless pursuit of answers through rigorous clinical trials offers promise for improved treatments and better outcomes for patients affected by this complex disease. Each step forward brings us closer to conquering Hodgkin's lymphoma once and for all.
Which are the best cities for hodgkin's lymphoma clinical trials?
When it comes to Hodgkin's lymphoma clinical trials, several cities in the United States stand out as hubs for innovative research. New york boasts 27 active trials studying treatments like CC-122 and JNJ-67856633. Houston, Texas follows closely with 25 ongoing studies focusing on MABEL CTLs and Antigen-Escalation Stage approaches. Meanwhile, Chicago, Los Angeles, and Denver also contribute significantly to the field with their respective 17, 16, and 15 active trials exploring various treatment options. These cities serve as crucial centers of advancement for individuals seeking cutting-edge therapies for Hodgkin's lymphoma.
Which are the top treatments for hodgkin's lymphoma being explored in clinical trials?
Exciting developments are underway in the field of Hodgkin's lymphoma research, with several cutting-edge treatments showing promise in ongoing clinical trials. Leading the pack is pembrolizumab, currently being explored in two active trials and having a total of 27 all-time studies dedicated to Hodgkin's lymphoma. Rituximab follows closely behind, also involved in two active trials and boasting an impressive 22 all-time clinical trials since its introduction in 1999. Another notable contender is EPOCH, with two ongoing trials focusing on this treatment option that first appeared on the scene back in 2009. Lastly, we have relatlimab—the newest addition to the lineup—currently under investigation in one active trial but already making waves as a potential game-changer for patients battling Hodgkin's lymphoma since its listing just this year (2022). These innovative therapies offer hope for improved outcomes and quality of life for individuals affected by this challenging disease.
What are the most recent clinical trials for hodgkin's lymphoma?
Recent clinical trials offer promising advancements in the treatment of Hodgkin's lymphoma. CAR-T cell therapy, a groundbreaking approach that harnesses the power of genetically modified immune cells, has shown potential in Phase 2 trials. Another study explores the use of anti-CD30 bispecific antibody-armed autologous T-cells to target and eliminate cancer cells—a hopeful development in Phase 1 and Phase 2 trials. Additionally, pembrolizumab demonstrates encouraging results as an immunotherapy option for patients with Hodgkin's lymphoma, while relatlimab shows promise as a treatment option during both Phase 1 and Phase 2 studies. Lastly, M+P (Arm A) is being evaluated through a large-scale Phase 3 trial to determine its efficacy in treating this form of lymphoma. With these innovative approaches paving the way forward, individuals battling Hodgkin's lymphoma can find solace in these advancements on their journey towards recovery.
What hodgkin's lymphoma clinical trials were recently completed?
Recent advancements in clinical trials for Hodgkin's lymphoma have paved the way for improved treatment options. In September 2019, ADC Therapeutics S.A. completed a trial investigating Camidanlumab Tesirine, an innovative therapy that shows promise against this type of cancer. Another significant milestone was reached in May 2018 when SCRI Development Innovations, LLC concluded their trial on Nivolumab, offering potential new avenues for patients with Hodgkin's lymphoma. Additionally, M.D. Anderson Cancer Center made notable progress with their study on Mycophenolate Mofetil, completing it in October 2017 and contributing valuable insights to enhance treatment strategies. These recent clinical trials demonstrate remarkable dedication from researchers worldwide as they strive to improve outcomes for individuals affected by Hodgkin's lymphoma.